Imunon Inc (IMNN)

US · Healthcare · Biotechnology

$1.38-2.13%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Net profit

$-2.8M

EPS

$-0.54

EPS estimate

$-0.94

EPS came in at -0.54 against a street estimate of -0.94 — a beat of 42.6%.

Market cap

$8.5M

Forward P/E

16.8

P/B

2.10

Book value

$0.41

EPS (TTM)

$-2.92

52-week high

$5.85

52-week low

$1.47

50-day MA

$1.69

200-day MA

$2.73

Beta

1.98

Analysts rate Imunon Inc a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $17.00.

Insiders

5.46%

Institutions

5.68%

Fund	Stake
Armistice Capital, LLC	8.29%
Vanguard Capital Management, LLC	1.14%
Riverview Capital Advisers LLC	0.82%
Geode Capital Management, LLC	0.79%
Vanguard Fiduciary Trust Co	0.32%
HRT FINANCIAL LLC	0.29%
BlackRock Inc	0.11%
Wells Fargo & Co	0.08%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Imunon Inc — free to start.

Data updated 2026-09-18.